Raritan, NJ (November 9, 2007) - Findings from three phase III clinical trials of rivaroxaban will be presented in the plenary session and during oral presentations at the American Society of Hematology (ASH) Annual Meeting in Atlanta, Georgia, from December 8 to 11, 2007. Rivaroxaban is being jointly developed by Johnson & Johnson Pharmaceutical Research & Development, L.L.C. and Bayer HealthCare, AG.
The studies evaluated rivaroxaban in head-to-head comparison with enoxaparin, the current standard of care, for the prevention of venous thromboembolism (VTE) in patients undergoing major orthopaedic surgery. The presentations will highlight results from the recently-completed RECORD1 (Regulation of Coagulation in major Orthopaedic surgery reducing the Risk of DVT and PE) and RECORD2 studies in total hip replacement surgery as well as additional data from the RECORD3 trial, which evaluated rivaroxaban in total knee replacement surgery. Copies of the following abstracts can be viewed online at the ASH website: www.hematology.org/meetings/abstracts.cfm.

Information beyond what is contained in the abstract is embargoed until the start time of the official annual meeting presentation.

• Oral Rivaroxaban Compared with Subcutaneous Enoxaparin for Extended Thromboprophylaxis after Total Hip Arthroplasty: The RECORD1 Trial Abstract# 6. Plenary presentation: Sunday, Dec. 9, 3:10 p.m., Hall A1, Georgia World Congress Center


• Extended Thromboprophylaxis with Rivaroxaban Compared with Short-Term Thromboprophylaxis with Enoxaparin After Total Hip Arthroplasty: The RECORD2 Trial

Abstract# 307. Oral presentation: Monday, Dec. 10, 11:00 a.m., Rooms B312-B313a

• Abstract# 307. Oral presentation: Monday, Dec. 10, 11:00 a.m., Rooms B312-B313a

Abstract# 308. Oral presentation: Monday, Dec. 10, 11:15 a.m., Rooms B312-B313a

Four additional abstracts will be presented as poster presentations on Saturday, December 8 and Sunday, December 9, 2007.

Johnson & Johnson Pharmaceutical Research and Development

Johnson & Johnson Pharmaceutical Research & Development, L.L.C. (J&JPRD), is part of Johnson & Johnson, the world's most broadly based producer of healthcare products. J&JPRD is headquartered in Raritan, NJ, and has facilities throughout Europe and the United States. J&JPRD is leveraging drug discovery and drug development in a variety of therapeutic areas to address unmet medical needs worldwide.

(This press release contains "forward-looking statements" as defined in the Private Securities Litigation Reform Act of 1995. These statements are based on current expectations of future events. If underlying assumptions prove inaccurate or unknown risks or uncertainties materialize, actual results could vary materially from J&JPRD's expectations and projections. Risks and uncertainties include general industry conditions and competition; economic conditions, such as interest rate and currency exchange rate fluctuations; technological advances and patents attained by competitors; challenges inherent in new product development, including obtaining regulatory approvals; domestic and foreign health care reforms and governmental laws and regulations; and trends toward health care cost containment. A further list and description of these risks, uncertainties and other factors can be found in

Exhibit 99 of Johnson & Johnson's Annual Report on Form 10-K for the fiscal year ended December 31, 2006. Copies of this Form 10-K, as well as subsequent filings, are available online at www.sec.gov, www.jnj.com or on request from Johnson & Johnson. J&JPRD does not undertake to update any forward-looking statements as a result of new information or future events or developments.)